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INTRODUCTION {#sec1-1}
============

Cancer-related pain represents a challenge to manage medically, and most patients will require higher and higher doses of opioid analgesics due to receptor downregulation, which puts them at risk of opioid addiction and death.\[[@ref6]\] Utilizing an optimal noninvasive medical treatment, about 30% of patients will have refractory pain, thus requiring invasive pain procedures to achieve partial or complete relief.\[[@ref5]\] Different invasive pain procedural options include anterolateral cordotomy, spinal cord stimulation, and intrathecal pain pump (ITPP).\[[@ref2],[@ref3]\] Here, we present a cost analysis of in-hospital intravenous (IV) narcotics, anterolateral cordotomy versus ITPP placement in two terminal cancer patients.

CASE DESCRIPTION {#sec1-2}
================

Case 1 {#sec2-2_1}
------

A 53-year-old female with metastatic breast cancer presented with severe pain involving the right chest wall; her n expected survival was \<1 year. She had failed oral narcotics and was admitted for 7 days of Dilaudid patient-controlled analgesia (PCA); nevertheless, this left her with a 5/10 residual pain score. She, therefore, underwent a left-sided C1-2 cordotomy which resulted in immediate pain relief. The PCA was weaned over 2 days and she was discharged home in stable condition. The total cost of her care was \$108,346; \$18,462 for the cordotomy, \$89,884 for the hospital stay \[[Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}\].

###### 

Patient demographics.
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###### 

Details of the pain procedures cost.
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Case 2 {#sec2-2_2}
------

A 60-year-old female with metastatic breast cancer and an expected survival of \<1 year presented with severe cancer- related pain involving the left knee cap. She failed oral narcotics and local nerve blocks. She was admitted for Dilaudid PCA, but her residual pain was 7/10 on the VAS, so she underwent ITPP placement. Immediately postoperatively she experienced partial pain relief and the PCA was weaned over 7 days (e.g., to titrate the intrathecal opioids), at which point she was discharged home. The total cost of her care totaled \$165,389; \$80,603 for the ITPP placement procedure (including the implants) and \$84,786 for the hospital stay \[[Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}\].

DISCUSSION {#sec1-3}
==========

In 1986, the World Health Organization stated the following "to provide relief from pain to the patient's satisfaction, so that \[they\] may function effectively and eventually die free from pain" in regard to cancer-related pain.\[[@ref8]\] Yet, multiple reports have shown that a significant percentage of patients with cancer pain is undertreated and suggest that the majority of these patients may benefit from interventional pain procedures.\[[@ref4]\] Percutaneous cervical cordotomy provides immediate and long-lasting relief of unilateral somatic pain in about 90% of patients, with a low complication rate of \<5%.\[[@ref3]\] ITPP acts by delivering minute doses of opioids intrathecally, which causes pain relief without the untoward side effects of IV and oral opioids. A recent randomized controlled trial showed that 85.7% of patients randomized to receive a cordotomy experienced \>33% reduction in pain intensity (≥4 points), while none randomized to palliative care achieved a similar reduction in pain.\[[@ref7]\] Corrado et al. found that ITPP resulted in a 4.2-point reduction of the pain score (9.1--4.9 on 10-point pain scale) in two-thirds of their cancer patients, while Brogan et al. showed that ITPP achieved cost-effectiveness at 7.6 and 10.7 months versus high and low conventional opioid therapy, respectively.\[[@ref1]\] In this report, the cost of the cordotomy (\$18,462) was 22.9% of the cost of ITPP (\$80,603) and 27% that of in-hospital PCA for ITTP titration.

Cost summary {#sec2-3_1}
------------

In a cancer patient with expected survivals of \<1 year, cordotomy saved about \$57,053 in total cost versus ITPP. Therefore, for patients with estimated survivals of under 1 year, cordotomy was the most cost-effective versus ITPP in which is a better option in cancer patients with survival estimated at \>1 year.

CONCLUSION {#sec1-4}
==========

There is an obvious need for cost effective and adequate treatment for cancer-related pain. This study documented the lesser costs but comparable efficacy of utilizing cordotomy to treat patients with estimated survivals of \<1 year versus the recommendation to consider ITPP for those with \>1 year to live.

**How to cite this article:** Aljuboori Z, Burke W, Meyer K, Williams B. Cost analysis of cordotomy and intrathecal pain pump placement for refractory cancer pain. Surg Neurol Int 2020;11:72.

Declaration of patient consent {#sec1-5}
==============================

Patient's consent not required as patient's identity is not disclosed or compromised.

Financial support and sponsorship {#sec1-6}
=================================

Nil.

Conflicts of interest {#sec1-7}
=====================

There are no conflicts of interest.
